ADMA Biologics Inc

2.03-0.0400-1.93%Vol 2.43M1Y Perf 33.55%
Aug 9th, 2022 16:00 DELAYED
BID2.00 ASK2.10
Open2.05 Previous Close2.07
Pre-Market- After-Market1.99
 - -  -0.04 -1.97%
Target Price
5.17 
Analyst Rating
Strong Buy 1.00
Potential %
154.68 
Finscreener Ranking
★★★     49.40
Insiders Trans % 3/6/12 mo.
-/-/100 
Value Ranking
     41.64
Insiders Value % 3/6/12 mo.
-/-/100 
Growth Ranking
★★     44.42
Insiders Shares Cnt. % 3/6/12 mo.
-/-/100 
Income Ranking
 —    -
Price Range Ratio 52W %
74.45 
Earnings Rating
Strong Buy
Market Cap398.59M 
Earnings Date
10th Aug 2022
Alpha-0.00 Standard Deviation0.17
Beta1.02 

Today's Price Range

1.972.09

52W Range

1.012.38

5 Year PE Ratio Range

-1.60-3.50

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Sell
Performance
1 Week
-0.96%
1 Month
-10.39%
3 Months
34.42%
6 Months
23.95%
1 Year
33.55%
3 Years
-40.52%
5 Years
-31.91%
10 Years
-

TickerPriceChg.Chg.%
ADMA2.03-0.0400-1.93
AAPL164.920.05000.03
GOOG117.50-0.6400-0.54
MSFT282.301.98000.71
XOM90.591.64001.84
WFC43.400.21000.49
JNJ170.18-0.0200-0.01
FB196.640.99000.51
GE74.93-0.2500-0.33
JPM115.381.03000.90
 
ProfitabilityValueIndustryS&P 500US Markets
7.00
-69.20
-62.90
-197.30
-77.95
RevenueValueIndustryS&P 500US Markets
76.17M
0.39
61.94
42.00
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.08-0.10-25.00
Q04 2021-0.10-0.0910.00
Q03 2021-0.15-0.1313.33
Q02 2021-0.15-0.150.00
Q01 2021-0.17-0.165.88
Q04 2020-0.17-0.20-17.65
Q03 2020-0.21-0.199.52
Q02 2020-0.19-0.23-21.05
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.0811.11Positive
9/2022 QR-0.0712.50Positive
12/2022 FY-0.296.45Positive
12/2023 FY-0.15-15.38Negative
Next Report Date10th Aug 2022
Estimated EPS Next Report-0.09
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume2.43M
Shares Outstanding196.35K
Shares Float188.45M
Trades Count8.14K
Dollar Volume4.92M
Avg. Volume1.83M
Avg. Weekly Volume1.34M
Avg. Monthly Volume1.61M
Avg. Quarterly Volume2.52M

ADMA Biologics Inc (NASDAQ: ADMA) stock closed at 2.07 per share at the end of the most recent trading day (a -3.27% change compared to the prior day closing price) with a volume of 2.17M shares and market capitalization of 398.59M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 314 people. ADMA Biologics Inc CEO is Adam S. Grossman.

The one-year performance of ADMA Biologics Inc stock is 33.55%, while year-to-date (YTD) performance is 46.81%. ADMA stock has a five-year performance of -31.91%. Its 52-week range is between 1.01 and 2.38, which gives ADMA stock a 52-week price range ratio of 74.45%

ADMA Biologics Inc currently has a PE ratio of -4.80, a price-to-book (PB) ratio of 3.56, a price-to-sale (PS) ratio of 5.39, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -28.79%, a ROC of -26.78% and a ROE of -65.38%. The company’s profit margin is -77.95%, its EBITDA margin is -62.90%, and its revenue ttm is $76.17 Million , which makes it $0.39 revenue per share.

Of the last four earnings reports from ADMA Biologics Inc, there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.09 for the next earnings report. ADMA Biologics Inc’s next earnings report date is 10th Aug 2022.

The consensus rating of Wall Street analysts for ADMA Biologics Inc is Strong Buy (1), with a target price of $5.17, which is +154.68% compared to the current price. The earnings rating for ADMA Biologics Inc stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

ADMA Biologics Inc has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

ADMA Biologics Inc has a Neutral technical analysis rating based on Technical Indicators (ADX : 19.23, ATR14 : 0.12, CCI20 : -84.30, Chaikin Money Flow : 0.03, MACD : -0.01, Money Flow Index : 50.26, ROC : -7.59, RSI : 35.89, STOCH (14,3) : 23.08, STOCH RSI : 0.59, UO : 45.26, Williams %R : -76.92), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of ADMA Biologics Inc in the last 12-months were: Adam S. Grossman (Buy at a value of $350 000), Brian Lenz (Buy at a value of $30 000), Jerrold B. Grossman (Buy at a value of $100 000), Young T. Kwon (Buy at a value of $100 000)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (100.00 %)
2 (100.00 %)
2 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

ADMA Biologics Inc

ADMA Biologics Inc is a United States-based biopharmaceutical company. It is engaged in the manufacture, marketing and development of specialty plasma-derived biologics. The operating segments of the company are ADMA BioManufacturing segment; Plasma Collection Centers segment; and Corporate segment. The Plasma Collection Centers segment consists of three FDA-licensed source plasma collection facilities located in Georgia. The company's ADMA BioManufacturing segment reflects the company's immune globulin manufacturing and development operations in Florida.

CEO: Adam S. Grossman

Telephone: +1 201 478-5552

Address: 465 State Route 17, Ramsey 07446, NJ, US

Number of employees: 314

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

61%39%

Bearish Bullish

66%34%

Bearish Bullish

55%45%


News

Stocktwits